Sexual Dysfunction from Psychotropic Drugs and SSRIs

Neurochemical Impact of SSRI Antidepressants

The use of psychotropic medications represents one of the main iatrogenic causes observed in clinical sexological eva luation.

Within this group, selective serotonin reuptake inhibitors (SSRIs) have a profound impact on all phases of the erotic response.

Elevated levels of central serotonin generate a descending inhibitory effect on dopaminergic and noradrenergic pathways, neurotransmitters that are essential for the modulation of sexual desire and arousal.

Clinically, this neurochemical imbalance results in a marked reduction in libido, anorgasmia or severe orgasmic delay, delayed ejaculation in men, and a marked reduction in lubrication in women.

These changes can become established as early as the first few weeks of prescribed drug therapy and severely impair the patient’s adherence to treatment, requiring rapid identification and intervention by a clinical sexologist.

Hormonal Alterations and Inhibition by Antipsychotics

Neuroleptics and antipsychotics induce sexual dysfunction through intertwined neurochemical and endocrine pathways.

Antagonism of D2 dopamine receptors in the central nervous system disrupts the tuberoinfundibular pathway, triggering significant secondary hyperprolactinemia.

The increase in prolactin inhibits the hypothalamic-pituitary axis, blocking the release of gonadotropin-releasing hormone and causing a drastic decrease in testosterone synthesis. This hormonal suppression severely diminishes sexual desire in both sexes.

At the same time, in men it causes erectile dysfunction, while in women it leads to vaginal epithelial atrophy, clitoral hypotumescence, and insufficient lubrication, resulting in dyspareunia.

Furthermore, the alpha-adrenergic and anticholinergic blocking effects of these drugs impair the vascular reflexes associated with arousal and cause ejaculatory disorders such as retrograde ejaculation. The associated sedation also reduces the level of alertness necessary for stimulation.

Effects of Anxiolytics and Interdisciplinary Therapeutic Management

Benzodiazepines and other anxiolytics alter sexual functioning by enhancing GABAergic neurotransmission.

Although they reduce performance anxiety and promote disinhibition in acute interventions, their continued use depresses overall brain activity.

This central depression dulls erotic responsiveness, reduces genital vasocongestion, and inhibits orgasmic responses.

For an accurate diagnosis of iatrogenic dysfunction, the clinical eva luation must establish a rigorous timeline linking the introduction or modification of the psychotropic medication to the onset of the presenting complaint.

The approach requires interdisciplinary coordination with the prescribing physician to avoid abrupt discontinuation of the medication.

Clinical strategies include gradual dose reduction, switching to psychotropic medications with less impact on the dopaminergic or vascular systems, and the use of adjunctive medications.